[1] .Lu, F. Payvandi, L. Wu, L. Zhang, R.J. Hariri, H. Man, R.S. Chen, The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions, Microvas. Res., 77 (2009) 78-86.
[2] E. Balaian, C. Schuster, C. Schönefeldt, U. Germing, D. Haase, S.Tuve, R. Ordemann, Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q, Ann. Hematol., 95 (2016) 1805-1810.
[3] a) Ch. Grondal, M. Jeanty, D. Enders, Organocatalytic cascade reactions as a new tool in total synthesis, Nature
chem., 2, 3 (2010) 167. b) M. Bakherad, A. Keivanloo, M. Siavashi, M. Omidian, Three-component synthesis of imidazo [1, 2-c] pyrimidines using silica sulfuric acid (SSA), Chin. Chem. Lett. 25 (2014) 149-151; c) M. Bakherad, A. Keivanloo, M. Omidian, S. Samangooei, Synthesis of pyrrolo [2, 3-b] pyrazines through Sonogashira coupling reaction of 5, 6-dichloropyrazine-2, 3-dicarbonitrile with hydrazine, phenylacetylene and various aldehydes, J Chem. Res. 38 (2014) 762-764.
[4] H. Sarma, T. Jahan, H.K. Sharma, Progress in Drug and Formulation Development for the Chemoprevention of Oral Squamous Cell Carcinoma: A Review, Recent Pat. Drug Deliv. Formul., 13 (2019) 16-36.
[5] S. Görög, Critical review of reports on impurity and degradation product profiling in the last decade, TrAC Trends Anal. Chem., 101 (2018) 2-16.
[6] B.G. Yilmaz, B. Nazik, K. Kucukoglu, GC-MS Determination of MexiletineAfter Derivatization with N-Methyl-N-(Trimethylsilyl) Trifluoroacetamide in Pharmaceutical Formulatios and Comparison with HPLC Method, Pharm. Chem. J., 51 (2017) 516-521.
[7] A.G. Osman, S. Haider, A.G. Chittiboyina, I.A. Khan, Utility of alkaloids as chemical and biomarkers for quality, efficacy, and safety assessment of botanical ingredients, Phytomedicine 54 (2019) 347-356.
[8] G.B.M. Saravanan, M. Rao, M.V. Ravikumar, N. Suryanarayana, P.V.R. Someswararao, P. Acharyulu. Development of an HPLC assay method for lenalidomide, Chromatographia 66 (2007) 287-290.
[9] N.S. Raghu, Y.R. Reddy, V. Naresh, V.S. Rao, L. K. Ravindranath, Degradation Studies of Highly Potent and Life Threatening Human Birth Defect Drug—Lenalidomide by HPLC and LC-MS, J Liq. Chromatogr. Relat. Technol., 33 (2010) 654-679.
[10] L.M. Reddy, K.J. Reddy, K.L.B. Reddy, P.R. Reddy, Development of a rapid and sensitive HPLC assay method for lenalidomide capsules and its related substances, J Chem., 9 (2012) 1165-1174.
[11] N.Z. Alzoman, A validated stability-indicating and stereoselective HPLC method for the determination of lenalidomide enantiomers in bulk form and capsules, J chromatogr. Sci., 54 (2016) 730-735.
[12] S.S. Prasad, G.V.K. Mohan, A.N. Babu, Development and Validation of Stability-Indicating RP-HPLC Method for the Estimation of Lenalidomide and its Impurities in Oral Solid Dosage form, Orient. J. Chem., 35 (2019) 140-149.
[13] A. Aristizábal, G. Perilla, J.A. Lara-Borrero, R. Diez, KrCl and XeCl excilamps and LP-Hg lamp for UV and UV/H2O2 decolourization of dyes in water, Environ. technol., 41 (2020) 238-250.